Zibo guansheng chemical co. LTD
Contact: manager gao
Contact number: 86-0533-5887828
Fax number: 86-0533-5887829
Mobile phone number: 13581018111
Web site: www.chinaguansheng.cn
Company address: longquan industrial park, zibo city, shandong province, China
In the future, China's pharmaceutical industry is showing four development trends:
First, the domestic competition internationalization, the international competition localization. This is reflected in the strengthened integration of China and the world. China has become a competitive and manufacturing center, and its position in the world has been further consolidated.
The capital operation of the pharmaceutical industry is active and the cooperation is obviously strengthened. Foreign-funded enterprises have accelerated their mergers and acquisitions or cooperation in China to gain direct access to the Chinese market, and the amount of foreign direct investment in pharmaceutical manufacturing in China has continuously increased.
Second, independent innovation has become an upsurge, which is reflected in the government's increased policy and financial support for research and development, and enterprises' increased investment in research and development. In the past few years, the state has stepped up efforts to encourage breakthrough innovation in research and development.
Local enterprises also pay more attention to innovative research and development. The proportion of independent research and development investment in sales revenue of Chinese pharmaceutical enterprises is 1%~2% on average, which will be significantly increased in the next five years, and the gap between research and development intensity and multinational enterprises will gradually narrow.
Third, the trend of diversified development is obvious, which is manifested in horizontal cross-border, vertical mergers and acquisitions and channel extension. Horizontal diversification enables pharmaceutical enterprises to develop from drug manufacturing to the field of big health. Domestic mainstream enterprises such as Harbin pharmaceutical, guangzhou pharmaceutical and kangenbei have achieved good brand and economic benefits, and many enterprises have been developing towards the field of big health. Vertical diversification is manifested in the increase of mergers and acquisitions between industrial enterprises and industrial and commercial enterprises, and the trend of enterprises' integration into the upstream and downstream resources of the industrial chain is very obvious. The diversification of channels is reflected in the extension of physical channels to virtual channels, including the modes of quick batch, quick distribution, affordable drugstores, professional agents and third-party agents, and the gradual development of e-commerce businesses such as B2B, B2C and e-commerce platforms.
Fourth, the concentration of the industry increased rapidly. The promotion and implementation of the basic drug system, the implementation of the two-envelope model for drug bidding, the consistency evaluation of generic drug requirements and the new GMP and other policies will promote the acceleration of mergers and acquisitions in the industry.
In the context of accelerated industrial upgrading and transformation, the development of China's pharmaceutical economy will face two obstacles. In the short term, the first is to limit the growth rate of hospital drug costs and the cost control of medical insurance payment reform. Second, the price policy changes, especially the circulation rate control, policy implementation needs to be further clarified. In the medium term, first, the implementation of the new GMP will lead to the increase of fixed costs caused by enterprise investment, which will promote the capital operation of the pharmaceutical industry. Second, the consistency evaluation of generic drugs.